Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35
Kiniksa Pharmaceuticals Analyst Ratings
Jefferies Initiates Kiniksa Pharmaceuticals at Buy With $40 Price Target
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Kiniksa Pharmaceuticals Analyst Ratings
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating
Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.
Kiniksa Pharmaceuticals Analyst Ratings
Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Komo: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $26.00 to $30.00.
Kiniksa Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Kiniksa Pharmaceuticals Analyst Ratings
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects